Kidney Function And The Effectiveness And Safety Of Direct Oral Anticoagulants In Atrial Fibrillation: The KODIAK-AF Study
Funder
National Health and Medical Research Council
Funding Amount
$451,730.00
Summary
The direct oral anticoagulants (DOACs) are a relatively new type of drug that are used to prevent the onset of stroke among patients with atrial fibrillation (AF). While these drugs have been demonstrated to be safe and effective among AF patients, in those AF patients with chronic kidney disease (CKD), there is uncertainty as to whether these drugs are similarly safe. This program of research will study the safety profile of DOACs in patients with AF and CKD.
Cardiovascular Risk Reduction In Atrial Fibrillation (CRAFT)
Funder
National Health and Medical Research Council
Funding Amount
$153,975.00
Summary
Atrial Fibrillation (AF) affects 240,000 Australians and rates of AF are rising. AF presents a significant economic burden. AF is debilitating and increases the risk of stroke, heart failure, or premature death. People with AF have high levels of cardiovascular risk and recommendations suggest they make lifestyle changes. These recommendations are not strongly evidence based. We aim to test if a lifestyle intervention can improve adherence and develop evidence to support the recommendations.
Optimising The Management Of Patients With Atrial Fibrillation - The Standard Vs Atrial Fibrillation SpEcific ManagemenT StudY (SAFETY)
Funder
National Health and Medical Research Council
Funding Amount
$65,040.00
Summary
To optimise the management of patients with AF, we will conduct an intervention clinical trial, the goal of which is to develop and implement a care program that aims to improve the health of patients with AF. This will be done by comparing the usual care that patients would normally receive in hospital and in the community with a specialised and individualised health care program - the Standard vs Atrial Fibrillation spEcific managemenT studY (SAFETY).
The Increasing Burden Of Stroke With Ageing: Using CARAT To Optimise Preventative Treatment In The Community
Funder
National Health and Medical Research Council
Funding Amount
$709,036.00
Summary
This clinical trial will test whether a novel clinical tool can assist GPs in improving the prevention of stroke in the community, especially in older people and those with atrial fibrillation (an irregular heartbeat). This tool, called CARAT (Computerised Antithrombotic Risk Assessment Tool), has been developed to help GPs calculate a patient's risk of stroke and then identify the optimal preventative medicine. Selecting appropriate therapy is important to prevent stroke and avoid side-effects.